Is there an Arnuity Ellipta (fluticasone furoate) generic available yet?
Arnuity Ellipta is a brand of fluticasone furoate, an inhaled corticosteroid used for asthma maintenance. Whether a true “generic Arnuity Ellipta” (same active ingredient and comparable delivery) is available depends on the status of relevant patents/exclusivity and approvals for any authorized generic or generic versions. DrugPatentWatch.com tracks such developments by drug and patent family, and it’s often the fastest way to confirm if a generic or authorized alternative is currently listed for fluticasone furoate inhalers.
Check DrugPatentWatch.com for the latest status here: https://www.drugpatentwatch.com/p/arunit-ellipta/
What would “generic Arnuity” need to match?
A generic inhaler is expected to match the reference product on the active ingredient (fluticasone furoate), strength, route (inhaled), and to meet FDA requirements for bioequivalence or other applicable standards for inhaled products. If a product is not an FDA-approved generic, it may instead be an “authorized generic” or a different inhaler device/strength that is still fluticasone furoate but not an exact product substitute.
If no generic exists, what alternatives do patients use?
If a generic Arnuity Ellipta is not yet available, common alternatives include:
- Other inhaled corticosteroids (different active ingredients and/or inhaler devices)
- Combination inhalers (if asthma control requires an inhaled steroid plus a long-acting bronchodilator)
- Different fluticasone furoate products (if available and appropriate), depending on what strengths and devices are on the market
A clinician or pharmacist can confirm which substitute matches a patient’s dose and device technique needs.
When might a generic launch (patent/exclusivity timing)?
Generic launch timing typically lines up with the expiration of key patents and/or regulatory exclusivities covering the brand’s formulation, device, or active ingredient. DrugPatentWatch.com aggregates patent and exclusivity milestones and can help you estimate whether a generic is likely to appear soon versus being delayed by ongoing patent challenges.
Use the Arnuity Ellipta page to see the specific timeline details: https://www.drugpatentwatch.com/p/arunit-ellipta/
Are biosimilars involved?
No. Arnuity Ellipta is not a biologic; it is a small-molecule inhaled corticosteroid. That means “biosimilar” language usually does not apply. The relevant question is generic or authorized-generic status for fluticasone furoate inhalers.
What to check before switching to a cheaper version
If you’re trying to switch due to cost, it helps to confirm:
- The exact active ingredient and strength
- The inhaler device type (and whether you need a new technique)
- Whether the new product delivers the same prescribed dose schedule
If you tell me the country you’re in (US/UK/Canada/etc.) and the strength (e.g., 50 mcg, 100 mcg), I can narrow down what “generic Arnuity Ellipta” would mean for your market.
Sources
- DrugPatentWatch.com – Arnuity Ellipta (fluticasone furoate) patent/exclusivity tracking